» Articles » PMID: 9826118

Cellular Mechanisms of Cardiac Hypertrophy

Overview
Specialty General Medicine
Date 1998 Nov 24
PMID 9826118
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertrophy of myocytes in the heart ventricles is an important adaptation that in vivo occurs in response to a requirement for increased contractile power. It involves changes at the level of gene transcription, stimulation of the rate of protein synthesis (translation), and increased assembly of myofibrils. There is mounting evidence of the involvement of reversible protein phosphorylation and dephosphorylation in most of these processes. Protein kinase C, mitogen-activated protein kinases, and transcription factors have been implicated in the modulation of the transcriptional changes. Activation of translation may also be mediated through protein phosphorylation/dephosphorylation, although this has not been clearly established in the heart. Here we provide a critical overview of the signalling pathways involved in the hypertrophic response and provide a scheme to account for many of its features.

Citing Articles

Cardiac arrhythmogenesis: roles of ion channels and their functional modification.

Lei M, Salvage S, Jackson A, Huang C Front Physiol. 2024; 15:1342761.

PMID: 38505707 PMC: 10949183. DOI: 10.3389/fphys.2024.1342761.


Cardiomyocyte electrophysiology and its modulation: current views and future prospects.

Huang C, Lei M Philos Trans R Soc Lond B Biol Sci. 2023; 378(1879):20220160.

PMID: 37122224 PMC: 10150219. DOI: 10.1098/rstb.2022.0160.


Angiotensin II-Induced Signal Transduction Mechanisms for Cardiac Hypertrophy.

Bhullar S, Dhalla N Cells. 2022; 11(21).

PMID: 36359731 PMC: 9657342. DOI: 10.3390/cells11213336.


Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice.

Alharbi H, Hardyman M, Cull J, Markou T, Cooper S, Glennon P Clin Sci (Lond). 2022; 136(22):1661-1681.

PMID: 36331065 PMC: 9679367. DOI: 10.1042/CS20220607.


Omentin inhibits the resistin-induced hypertrophy of H9c2 cardiomyoblasts by inhibiting the TLR4/MyD88/NF-κB signaling pathway.

Yan X, Wu L, Gao M, Yang P, Yang J, Deng Y Exp Ther Med. 2022; 23(4):292.

PMID: 35340867 PMC: 8931589. DOI: 10.3892/etm.2022.11222.